查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813402

2032 年生育表观基准化分析市场预测：按成分、技术、应用、最终用户和地区进行的全球分析

Fertility Epigenetic Benchmarking Market Forecasts to 2032 - Global Analysis By Component (Products and Services), Technology (DNA Methylation, Histone Modification and RNA Sequencing), Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球生育表观遗传基准化分析市场预计在 2025 年达到 6.5505 亿美元，到 2032 年将达到 22.2667 亿美元，预测期内的复合年增长率为 19.1%。

生育表观遗传基准化分析是对影响生殖健康、胚胎发育和不孕症结果的表观遗传标记的研究和分析。它为了解影响不孕症的基因调控、生活方式和环境因素提供了见解。由于不孕症率上升、受孕延迟趋势以及生殖医学的进步，这个新兴市场正日益受到关注。其应用涵盖诊断、辅助生殖技术 (ART) 和个人化治疗计划。生物技术、生育诊所和基因组学公司之间正在进行的研究与合作正在塑造生育表观遗传基准基准化分析的商业化。

根据世界卫生组织统计，全球约有六分之一的人一生中会经历不孕不育，凸显了不孕症评估的必要性，而评估是包括基准化分析遗传基准测试在内的高级诊断的基础。

全球不孕不育率上升

全球不孕症盛行率的上升是生育表观遗传学基准化分析市场发展的关键驱动因素。生育延迟、环境毒素和生活方式改变等因素都导致了不孕症盛行率的上升。因此，对先进诊断工具和个人化治疗方案的需求日益增长。表观遗传学分析能够深入了解基因表现模式，并有助于识别潜在的不孕症问题。这种方法有助于制定个人化介入措施，提高治疗效果和患者预后。此外，将表观遗传学数据整合到不孕症评估中正成为生殖医学的标准做法。

患者意识有限

生育表观遗传学基准化分析市场的一个重要限制因素是患者对錶观遗传学检测的益处和可用性缺乏认识。许多人仍然不了解表观遗传因素如何影响不孕症和生殖健康。这种认知的缺乏可能导致诊断延误，并错失早期疗育的机会。教育工作和宣传宣传活动对于让患者了解表观遗传因素在生育治疗中的重要性至关重要。病患知识的提升可以推动对表观遗传学检测和个人化生育治疗的需求。

生物科技与不孕症诊所的合作

生技公司和生育诊所拥有越来越多的合作机会，可以推动生育表观遗传学基准基准化分析领域的发展。伙伴关係可以促进整合表观遗传学见解的创新诊断工具和治疗方法的发展。此类合作可以提高不孕症评估的准确性和治疗的有效性。此外，共同努力可以促进知识和资源共用，加速生殖医学的研究和发展。此类伙伴关係有可能透过提供个人化和精准的解决方案，彻底改变生育治疗。

公众对表观遗传干预的怀疑

生育表观遗传学基准化分析市场面临的一个突出威胁是社会对表观遗传学介入的安全性和有效性的质疑。对改变表观遗传因素的长期影响和伦理影响的担忧，可能会阻碍患者选择此类治疗。这种质疑可能会阻碍基于表观遗传学的不孕症治疗的广泛应用。透过透明的沟通、严格的临床试验和伦理准则来解决这些问题，对于建立公众的信任和接受至关重要。

COVID-19的影响：

新冠疫情对生育表观遗传学基准化分析市场产生了多方面的影响。这场危机导致生育治疗中断，选择性手术暂停，影响了病患的医疗服务。此外，疫情也加剧了压力水平和经济不确定性，影响了生育决策，并推迟了生育计画。然而，这场危机加速了远端医疗和远距会诊在生育治疗的应用。此外，疫情凸显了生殖健康韧性的重要性，这可能会推动未来对创新生育治疗解决方案的投资。

预计预测期内产品细分市场规模最大

预计该产品细分市场将在预测期内占据最大的市场份额。此细分市场涵盖各种诊断工具、试剂和试剂套件，这些产品对于不孕症评估中的表观遗传学分析至关重要。个人化不孕症治疗需求的不断增长以及表观遗传学检测融入临床常规是推动该细分市场成长的主要因素。此外，产品开发的进步以及更有效率、更人性化的诊断工具的推出预计将进一步推动市场发展。

预计在预测期内，RNA 定序部分将以最高的复合年增长率成长。

RNA测序领域预计将在预测期内呈现最高成长率。 RNA定序能够全面分析基因表现，为不孕症的分子机制提供宝贵见解。 RNA定序在生殖医学研究中的应用日益广泛，其在识别不孕症生物标记方面的潜力正在推动其普及。此外，RNA定序技术的进步和成本的下降使得这种方法在临床环境中更加普及，从而促进了其快速成长。

占比最大的地区：

预计北美将在预测期内占据最大的市场份额。这一优势得益于该地区先进的医疗基础设施、高昂的医疗成本以及对研发的高度重视。此外，不孕症盛行率的上升以及对个人化不孕症治疗的需求不断增长，也推动了市场的成长。该地区成熟的生物技术产业和监管支持进一步促进了创新不孕症治疗方案的采用，从而巩固了其在市场上的主导地位。

复合年增长率最高的地区：

预计在预测期内，亚太地区生育表观遗传学基准化分析市场将迎来最高的复合年增长率。不孕症上升、生殖健康意识增强以及医疗基础设施的进步等因素促成了这一快速增长。该地区庞大的人口基数和不断发展的社会经济经济状况正在推动对生育治疗服务和个人化治疗的需求。此外，政府在生物技术研究方面的倡议和投资正在推动表观遗传学技术在生育治疗领域的创新和应用，使亚太地区成为重要的成长中心。

成分

  • 产品
  • 服务

提供免费客製化：

订阅此报告的用户可获得以下免费自订选项之一：

  • 公司简介
    • 全面分析其他市场参与者（最多 3 家公司）
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 二手研究资料
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球生育表观遗传基准基准化分析市场（按组成部分）

  • 产品
    • 套件和试剂
    • 设备及配件
  • 服务
    • DNA甲基化分析
    • 组蛋白修饰分析
    • 非编码RNA分析
    • 染色质结构分析

6. 全球生育表观遗传基准基准化分析市场（依技术）

  • DNA甲基化
    • 亚硫酸氢盐定序
    • 甲基化DNA免疫沉淀定序（MeDIP-Seq）
    • 其他DNA甲基化技术
  • 组蛋白修饰
    • 染色质免疫沉淀分析法（ChIP）
    • 组蛋白甲基化分析
    • 组蛋白乙酰化分析
  • RNA定序

7. 全球生育表观遗传基准基准化分析市场（按应用）

  • 男性不孕
  • 女性不孕症
  • 辅助生殖技术（ART）
    • 体外受精（IVF）
    • 卵细胞质内单一精虫显微注射术（ICSI）
    • 胚胎胚胎着床前基因检测（PGT）
  • 预测诊断和预后

8. 全球生育表观遗传基准基准化分析市场（依最终用户）

  • 不孕不育诊所和医院
  • 学术和研究机构
  • 製药和生物技术公司
  • 诊断实验室
  • 合约研究组织（CRO）

9. 全球生育表观基准化分析市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章：重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • Illumina
  • Thermo Fisher Scientific
  • Merck KGaA
  • QIAGEN
  • F. Hoffmann-La Roche
  • PacBio
  • Danaher
  • Bio-Rad Laboratories
  • Promega
  • New England Biolabs
  • Zymo Research
  • Hologic
  • Active Motif
  • Chroma Medicine
  • CooperSurgical
  • Inherent Biosciences
  • Vitrolife
  • Ferring Pharmaceuticals
Product Code: SMRC30851

According to Stratistics MRC, the Global Fertility Epigenetic Benchmarking Market is accounted for $655.05 million in 2025 and is expected to reach $2226.67 million by 2032 growing at a CAGR of 19.1% during the forecast period. Fertility epigenetic benchmarking is the study and analysis of epigenetic markers that influence reproductive health, embryo development, and fertility outcomes. It provides insights into genetic regulation, lifestyle impacts, and environmental factors affecting fertility. This emerging market is gaining attention due to rising infertility rates, delayed parenthood trends, and advancements in reproductive medicine. Applications span diagnostics, assisted reproductive technologies (ART), and personalized treatment planning. Ongoing research and collaborations between biotech, fertility clinics, and genomics firms are shaping the commercialization of fertility epigenetic benchmarking.

According to WHO, about 1 in 6 people worldwide experience infertility during their lifetime, highlighting the scale of fertility assessment needs that underpin advanced diagnostics, including epigenetic benchmarking.

Market Dynamics:

Driver:

Rising infertility rates globally

The escalating prevalence of infertility worldwide is a significant driver for the fertility epigenetic benchmarking market. Factors such as delayed childbearing, environmental toxins, and lifestyle changes contribute to this rise. Consequently, there is an increasing demand for advanced diagnostic tools and personalized treatment options. Epigenetic profiling offers insights into gene expression patterns, aiding in the identification of potential fertility issues. This approach facilitates tailored interventions, enhancing treatment efficacy and patient outcomes. Moreover, the integration of epigenetic data into fertility assessments is becoming a standard practice in reproductive medicine.

Restraint:

Limited awareness among patients

A significant restraint in the fertility epigenetic benchmarking market is the limited awareness among patients regarding the benefits and availability of epigenetic testing. Many individuals remain uninformed about how epigenetic factors influence fertility and reproductive health. This lack of awareness can lead to delayed diagnoses and missed opportunities for early intervention. Educational initiatives and awareness campaigns are essential to inform patients about the importance of epigenetic factors in fertility. Increasing patient knowledge can drive demand for epigenetic testing and personalized fertility treatments.

Opportunity:

Collaboration between biotech and fertility clinics

There is a growing opportunity for collaboration between biotechnology companies and fertility clinics to advance the field of fertility epigenetic benchmarking. Partnerships can lead to the development of innovative diagnostic tools and therapies that integrate epigenetic insights. Such collaborations can enhance the accuracy of fertility assessments and the effectiveness of treatments. Additionally, joint efforts can facilitate the sharing of knowledge and resources, accelerating research and development in reproductive medicine. These partnerships have the potential to revolutionize fertility care by offering personalized and precise solutions.

Threat:

Public skepticism of epigenetic interventions

A notable threat to the fertility epigenetic benchmarking market is public skepticism regarding the safety and efficacy of epigenetic interventions. Concerns about the long-term effects and ethical implications of modifying epigenetic factors can deter patients from opting for such treatments. This skepticism may hinder the widespread adoption of epigenetic-based fertility solutions. Addressing these concerns through transparent communication, rigorous clinical trials, and ethical guidelines is crucial to build public trust and acceptance.

Covid-19 Impact:

The COVID-19 pandemic has had a multifaceted impact on the fertility epigenetic benchmarking market. The crisis led to disruptions in fertility treatments and a temporary halt in elective procedures, affecting patient access to care. Moreover, the pandemic heightened stress levels and economic uncertainties, influencing reproductive decisions and delaying family planning. However, the crisis also accelerated the adoption of telemedicine and remote consultations in fertility care. Additionally, the pandemic underscored the importance of resilience in reproductive health, potentially driving future investments in innovative fertility solutions.

The products segment is expected to be the largest during the forecast period

The products segment is expected to account for the largest market share during the forecast period. This segment encompasses a wide range of diagnostic tools, reagents, and kits essential for epigenetic analysis in fertility assessments. The increasing demand for personalized fertility treatments and the integration of epigenetic testing into routine clinical practice are key factors driving the growth of this segment. Moreover, advancements in product development and the introduction of more efficient and user-friendly diagnostic tools are expected to further propel the market.

The RNA sequencing segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the RNA sequencing segment is predicted to witness the highest growth rate. RNA sequencing allows for comprehensive analysis of gene expression profiles, providing valuable insights into the molecular mechanisms underlying fertility. The increasing application of RNA sequencing in reproductive health research and its potential to identify biomarkers for fertility are driving its adoption. Additionally, technological advancements and decreasing costs associated with RNA sequencing are making this approach more accessible to clinical settings, contributing to its rapid growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share. This dominance is attributed to the presence of advanced healthcare infrastructure, high healthcare expenditure, and a strong focus on research and development in the region. Additionally, the increasing prevalence of infertility and the growing demand for personalized fertility treatments are propelling market growth. The region's well-established biotechnology sector and regulatory support further enhance the adoption of innovative fertility solutions, solidifying its leading position in the market.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR in the fertility epigenetic benchmarking market. Factors such as rising infertility rates, increasing awareness about reproductive health, and advancements in healthcare infrastructure contribute to this rapid growth. The region's large population base and evolving socio-economic conditions are driving the demand for fertility services and personalized treatments. Moreover, government initiatives and investments in biotechnology research are fostering innovation and adoption of epigenetic technologies in fertility care, positioning Asia Pacific as a key growth hub.

Key players in the market

Some of the key players in Fertility Epigenetic Benchmarking Market include Illumina, Thermo Fisher Scientific, Merck KGaA, QIAGEN, F. Hoffmann-La Roche, PacBio, Danaher, Bio-Rad Laboratories, Promega, New England Biolabs, Zymo Research, Hologic, Active Motif, Chroma Medicine, CooperSurgical, Inherent Biosciences, Vitrolife, and Ferring Pharmaceuticals.

Key Developments:

In February 2025, New England Biolabs presented latest innovations at AGBT 2025, showcasing the NEBNext Enzymatic Methyl-seq v2 kit that enables DNA input as low as 100 picograms, expanding applications for epigenetic research. Also featured new epigenetics tools including 5hmC detection, enzymatic DNA fragmentation, and chromatin structure analysis improvements.

In January 2025, QIAGEN partnered with Genomics England to support the Generation Study, providing clinically relevant variant content for genes in a point-of-care sequencing test to screen 100,000 newborns in England for over 200 treatable conditions.

In November 2024, PacBio announced formation of the HiFi Solves Sub-fertility Consortium, uniting leading experts and leveraging HiFi sequencing technology alongside DNAstack's federated data platform to advance diagnosis and treatment of subfertility and recurrent pregnancy loss.

Components:

  • Products
  • Services

Technologies Covered:

  • DNA Methylation
  • Histone Modification
  • RNA Sequencing

Applications Covered:

  • Male Infertility
  • Female Infertility
  • Assisted Reproductive Technology (ART)
  • Predictive Diagnostics and Prognostics

End Users Covered:

  • Fertility Clinics and Hospitals
  • Academic and Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Diagnostic Laboratories
  • Contract Research Organizations (CROs)

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Fertility Epigenetic Benchmarking Market, By Component

  • 5.1 Introduction
  • 5.2 Products
    • 5.2.1 Kits and Reagents
    • 5.2.2 Instruments and Accessories
  • 5.3 Services
    • 5.3.1 DNA Methylation Analysis
    • 5.3.2 Histone Modification Analysis
    • 5.3.3 Non-coding RNA Analysis
    • 5.3.4 Chromatin Structure Analysis

6 Global Fertility Epigenetic Benchmarking Market, By Technology

  • 6.1 Introduction
  • 6.2 DNA Methylation
    • 6.2.1 Bisulfite Sequencing
    • 6.2.2 Methylated DNA Immunoprecipitation Sequencing (MeDIP-Seq)
    • 6.2.3 Other DNA Methylation Technologies
  • 6.3 Histone Modification
    • 6.3.1 Chromatin Immunoprecipitation (ChIP)
    • 6.3.2 Histone Methylation Analysis
    • 6.3.3 Histone Acetylation Analysis
  • 6.4 RNA Sequencing

7 Global Fertility Epigenetic Benchmarking Market, By Application

  • 7.1 Introduction
  • 7.2 Male Infertility
  • 7.3 Female Infertility
  • 7.4 Assisted Reproductive Technology (ART)
    • 7.4.1 In Vitro Fertilization (IVF)
    • 7.4.2 Intracytoplasmic Sperm Injection (ICSI)
    • 7.4.3 Preimplantation Genetic Testing (PGT)
  • 7.5 Predictive Diagnostics and Prognostics

8 Global Fertility Epigenetic Benchmarking Market, By End User

  • 8.1 Introduction
  • 8.2 Fertility Clinics and Hospitals
  • 8.3 Academic and Research Institutes
  • 8.4 Pharmaceutical and Biotechnology Companies
  • 8.5 Diagnostic Laboratories
  • 8.6 Contract Research Organizations (CROs)

9 Global Fertility Epigenetic Benchmarking Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Illumina
  • 11.2 Thermo Fisher Scientific
  • 11.3 Merck KGaA
  • 11.4 QIAGEN
  • 11.5 F. Hoffmann-La Roche
  • 11.6 PacBio
  • 11.7 Danaher
  • 11.8 Bio-Rad Laboratories
  • 11.9 Promega
  • 11.10 New England Biolabs
  • 11.11 Zymo Research
  • 11.12 Hologic
  • 11.13 Active Motif
  • 11.14 Chroma Medicine
  • 11.15 CooperSurgical
  • 11.16 Inherent Biosciences
  • 11.17 Vitrolife
  • 11.18 Ferring Pharmaceuticals

List of Tables

  • Table 1 Global Fertility Epigenetic Benchmarking Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Fertility Epigenetic Benchmarking Market Outlook, By Component (2024-2032) ($MN)
  • Table 3 Global Fertility Epigenetic Benchmarking Market Outlook, By Products (2024-2032) ($MN)
  • Table 4 Global Fertility Epigenetic Benchmarking Market Outlook, By Kits and Reagents (2024-2032) ($MN)
  • Table 5 Global Fertility Epigenetic Benchmarking Market Outlook, By Instruments and Accessories (2024-2032) ($MN)
  • Table 6 Global Fertility Epigenetic Benchmarking Market Outlook, By Services (2024-2032) ($MN)
  • Table 7 Global Fertility Epigenetic Benchmarking Market Outlook, By DNA Methylation Analysis (2024-2032) ($MN)
  • Table 8 Global Fertility Epigenetic Benchmarking Market Outlook, By Histone Modification Analysis (2024-2032) ($MN)
  • Table 9 Global Fertility Epigenetic Benchmarking Market Outlook, By Non-coding RNA Analysis (2024-2032) ($MN)
  • Table 10 Global Fertility Epigenetic Benchmarking Market Outlook, By Chromatin Structure Analysis (2024-2032) ($MN)
  • Table 11 Global Fertility Epigenetic Benchmarking Market Outlook, By Technology (2024-2032) ($MN)
  • Table 12 Global Fertility Epigenetic Benchmarking Market Outlook, By DNA Methylation (2024-2032) ($MN)
  • Table 13 Global Fertility Epigenetic Benchmarking Market Outlook, By Bisulfite Sequencing (2024-2032) ($MN)
  • Table 14 Global Fertility Epigenetic Benchmarking Market Outlook, By Methylated DNA Immunoprecipitation Sequencing (MeDIP-Seq) (2024-2032) ($MN)
  • Table 15 Global Fertility Epigenetic Benchmarking Market Outlook, By Other DNA Methylation Technologies (2024-2032) ($MN)
  • Table 16 Global Fertility Epigenetic Benchmarking Market Outlook, By Histone Modification (2024-2032) ($MN)
  • Table 17 Global Fertility Epigenetic Benchmarking Market Outlook, By Chromatin Immunoprecipitation (ChIP) (2024-2032) ($MN)
  • Table 18 Global Fertility Epigenetic Benchmarking Market Outlook, By Histone Methylation Analysis (2024-2032) ($MN)
  • Table 19 Global Fertility Epigenetic Benchmarking Market Outlook, By Histone Acetylation Analysis (2024-2032) ($MN)
  • Table 20 Global Fertility Epigenetic Benchmarking Market Outlook, By RNA Sequencing (2024-2032) ($MN)
  • Table 21 Global Fertility Epigenetic Benchmarking Market Outlook, By Application (2024-2032) ($MN)
  • Table 22 Global Fertility Epigenetic Benchmarking Market Outlook, By Male Infertility (2024-2032) ($MN)
  • Table 23 Global Fertility Epigenetic Benchmarking Market Outlook, By Female Infertility (2024-2032) ($MN)
  • Table 24 Global Fertility Epigenetic Benchmarking Market Outlook, By Assisted Reproductive Technology (ART) (2024-2032) ($MN)
  • Table 25 Global Fertility Epigenetic Benchmarking Market Outlook, By In Vitro Fertilization (IVF) (2024-2032) ($MN)
  • Table 26 Global Fertility Epigenetic Benchmarking Market Outlook, By Intracytoplasmic Sperm Injection (ICSI) (2024-2032) ($MN)
  • Table 27 Global Fertility Epigenetic Benchmarking Market Outlook, By Preimplantation Genetic Testing (PGT) (2024-2032) ($MN)
  • Table 28 Global Fertility Epigenetic Benchmarking Market Outlook, By Predictive Diagnostics and Prognostics (2024-2032) ($MN)
  • Table 29 Global Fertility Epigenetic Benchmarking Market Outlook, By End User (2024-2032) ($MN)
  • Table 30 Global Fertility Epigenetic Benchmarking Market Outlook, By Fertility Clinics and Hospitals (2024-2032) ($MN)
  • Table 31 Global Fertility Epigenetic Benchmarking Market Outlook, By Academic and Research Institutes (2024-2032) ($MN)
  • Table 32 Global Fertility Epigenetic Benchmarking Market Outlook, By Pharmaceutical and Biotechnology Companies (2024-2032) ($MN)
  • Table 33 Global Fertility Epigenetic Benchmarking Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 34 Global Fertility Epigenetic Benchmarking Market Outlook, By Contract Research Organizations (CROs) (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.